SURVYR

OLMA

Olema Pharmaceuticals, Inc.
$7.04
+$0.42 (6.34%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-27%+58%+143%+228%+313%Oct 2025Oct 2026Apr 202652w high $36.2652w low $6.48
OLMASPY
Wall St. Highest PT $59.00 (+738.1%) Wall St. Avg PT $36.50 (+418.5%)
$6$25$44$62$81POC $12Hi $59Avg $36
Underwater Drawdown %Max DD -82.1%Current -80.4%
0.0%-82.1%
Relative Strength vs SPY-33.4% vs SPYUnderperforming
+355%0%-355%
1W
−$0.21 (2.90%)
1M
−$1.71 (19.54%)
3M
−$4.58 (39.41%)
6M
−$7.55 (51.75%)
YTD
−$17.96 (71.84%)
1Y
−$1.75 (19.91%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$7.04
Average target$36.50
+$29.46 (+418.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$16.00
Median$36.50
High$59.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$616.9M
P/E (next 12 months, estimated)-2.7
52-week range$6.48 – $36.26
Dividend yieldNo dividend
Average analyst price target$36.50 (+418%)

What they do

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for OLMA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

OLMA earningsNext report in 12 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Time not confirmed
EPS consensus-$0.63
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 10, 2026-$0.61est -$0.56−8.2%Below estimates
May 12, 2026-$0.52est -$0.54+3.5%Above estimates
Mar 16, 2026-$0.50est -$0.53+5.1%Above estimates
Nov 10, 2025-$0.49est -$0.45−8.5%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 17:56:26 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.610.17
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Harmon Cyrus
Director · 2026-07-24
Sell
$146.4K
Harmon Cyrus
Director · 2026-07-23
Sell
$144.7K
None
None · None
Sell
–

Stats refreshed 2026-10-27 17:56:26 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026